Recombinant human interleukin-10 fails to alter proinflammatory cytokine production or physiologic changes associated with the Jarisch-Herxheimer reaction

Journal of Infectious Diseases

Volumn 181, Issue 1, 2000, Pages 203-209

  Cooper, Philip J ^a,e,f   Fekade, Daniel ^b   Remick, Daniel G ^c   Grint, Paul ^d   Wherry, Janice ^d   Griffin, George E ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PENICILLIN DERIVATIVE; RECOMBINANT INTERLEUKIN 10; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD LEVEL; BORRELIA INFECTION; BORRELIA RECURRENTIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; HERXHEIMER REACTION; HUMAN; LEUKOCYTE FUNCTION; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; ETHIOPIA; FEVER; HUMANS; INFLAMMATION; INTERLEUKIN-10; MALE; RECOMBINANT PROTEINS; RECURRENCE; RELAPSING FEVER; SHOCK, SEPTIC;

EID: 0033958548     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315183     Document Type: Article

References (30)

1. 1. Bryceson ADM, Cooper KE, Warrell DA, Pertine PL, Parry EHO. Studies of the mechanisms of the Jarisch-Herxheimer reaction in louse-borne relapsing fever: evidence for the presence of circulating Borrelia endotoxin. Clin Sci 1972;43:343-54.
2. 2. Negussie Y. Remick DG, DeForge LE, Kunkel SL, Eynon A, Griffin GE. Detection of plasma tumor necrosis factor, interleukin-6, and 8 during the Jarisch-Herxheimer reaction of relapsing fever. J Exp Med 1992; 175: 1207-12.
3. 3. Bryceson ADM. Clinical pathology of the Jarisch-Herxheimer reaction. J Infect Dis 1976; 133:696-704.
4. 4. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318: 1481-6.
5. 5. Fekade D, Knox K, Hussein K, et al. Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor a. N Engl J Med 1996:335:311-15.
6. 6. Teklu B, Hapte-Michael A, Warrell DA, White NJ, Wright DJ. Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever. Lancet 1983;1:835-9.
7. 7. Moore KW, O'Garra A, de Waal Malefyt R, Vieira P, Mosmann TR. Interleukin 10. Annu Rev Immunol 1993; 11:165-90.
8. 8. Gomez-Jimenez J, Martin MC, Sauri R, et al. Interleukin-10 and the monocyte/macrophage-induced inflammatory response in septic shock. J Infect Dis 1995: 171:472-5.
9. 9. Bean AGD, Freiberg RA, Andrade S, Menon S, Zlotnick A. Interleukin-10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 1993:61:4937-9.
10. 10. Gerard C, Bruyns C, Marchant A, et al. Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med 1993; 177:547-50.
11. 11. Howard M, Muchamuel T, Andrade S, Menon S. Interleukin 10 protects mice from lethal endotoxemia. J Exp Med 1993; 177:1205-8.
12. 12. Keystone E, Wherry JC, Grint P. Interleukin-10 as a therapeutic strategy in the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 1998;24: 629-39.
13. 13. Pajkrt D, Camoglio L, Tiel-van Buul MCM, et al. Attenuation of proinflammatory response by recombinant human IL-10 in human endotoxemia: effect of timing of recombinant human IL-10 administration. J Immunol 1997; 158:3971-7.
14. 14. Chernoff AE, Granowitz EV, Shapiro L, et al. A randomized controlled study of IL-10 in humans: inhibition of inflammatory production and immune responses. J Immunol 1995; 154:5492-9.
15. 15. Eskandari MK, Nguyen DT, Kunkel SL, et al. WEHI 164 subclone 13 assay for TNF: sensitivity, specificity, and reliability. Immunol Invest 1990; 19: 69-79.
16. 16. DeForge LE, Takeuchi E, Nguyen DT, et al. Immunological priming attenuates the in vivo pathohysiological response to lipopolysaccharide. Comparison of cytokine production, tissue injury, and lethality in complete Freund's adjuvant-primed mice and in unprimed mice. Am J Pathol 1994; 144:599-611.
17. 17. Remick DG, Garg SJ, Newcomb DE, Wollenberg G, Huie TK, Bolgos GL. Exogenous interleukin 10 fails to decrease the mortality or morbidity of sepsis. Crit Care Med 1998;26:895-904.
18. 18. Munoz C, Carlet J, Fitting C, Misset B, Bleriot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-54.
19. 19. Opal SM, Wherry JC, Grint P. Interleukin-10: potential benefits and possible risks in clinical infectious diseases. Clin Infect Dis 1998;27:1497-507.
20. 20. Marchant A, Devicre J, Baudouin B, et al. Interleukin-10 production during septicemia. Lancet 1994:343:707-8.
21. 21. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-32.
22. 22. Friedman G, Janowski S, Marchant A, Goldman M, Kahn RJ, Vincent JL. Blood interleukin 10 levels parallel the severity of septic shock. J Crit Care 1997; 12:183-7.
23. 23. Van Dissel JT, van Langevelde P, Westendorp RGJ, Kwappenberg K, Frolich M. Antiinflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-3.
24. 24. Marchant A, Alegre ML, Hakim A, et al. Clinical and biological significance of interleukin-10 plasma levels in patients with septic shock. J Clin Immunol 1995; 15:266-73.
25. 25. Cassatella MA. The neutrophil: one of the cellular targets of interleukin-10. Int J Clin Lab Res 1998;28:148-61.
26. 26. Gosselin D, Desanetis J. Boule M, Skamene E, Matouk C, Radzioch D. Role of tumor necrosis factor α in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun 1995;63:3272-8.
27. 27. Greenberger MJ, Strieter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995; 155:722-9.
28. 28. van der Poll T, Marchant A, Keogh CV, Goldman M, Lowry SF. Interleukin 10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis 1996; 174:994-1000.
29. 29. van der Poll T, Keogh CV, Buurman WA, Lowry SF. Passive immunization against tumor necrosis factor-α impairs host defense during pneumococcal pneumonia in mice. Am J Respir Crit Care Med 1997; 155:603-8.
30. 30. Stordeur P, Goldman M. Interleukin-10 as a regulatory cytokine induced by cellular stress: molecular aspects. Int Rev Immunol 1998; 16:501-22.